Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > ARCHIVE
ARCHIVE
- Symyx to Introduce ELE to Japanese Companies
April 26, 2010
- Ethical Drugs Sales Up 2.3% in Jan., Flat in Feb.: Crecon
April 26, 2010
- Effects on MTPC's Business Performance Remain Unpredictable
April 26, 2010
- Osaka Bio Fund Inaugurated
April 26, 2010
- Administrative Sanction on MTPC Too Harsh: Mr Gohara
April 26, 2010
- Korosho Asks 4 Companies to Develop IPV
April 26, 2010
- Toho HD to Merge Asucome in October
April 26, 2010
- Carna Biosciences' R&D Project to Be Funded by NIBIO
April 26, 2010
- Mochida Terminates License Agreement for TRPV1 Antagonists with Wyeth
April 26, 2010
- CMIC Licenses L-FABP Diagnostic Technology to Genzyme
April 26, 2010
- Zeria Licenses Hemostatic, Wound Dressing Agents from HemCon
April 19, 2010
- Afinitor, Temodal Transiently Excluded from DPC Payment System
April 19, 2010
- Kobayashi Pharm. Spins Off Medical Device Division
April 19, 2010
- Bayer Integrates Intendis
April 19, 2010
- Requirements for Med Institutions Conducting Regenerative Medicine Notified
April 19, 2010
- Medwatcher Japan Presents Petition on Use of Unapproved Medical Devices
April 19, 2010
- CMIC Completes Acquisition of Daiichi Sankyo Propharma's Shizuoka Plant
April 19, 2010
- Q&A on Biosimilars Issued
April 19, 2010
- More than Just the Money
Philip Carrigan
Partner, Optia Partners
philip@optiapartners.com
April 19, 2010
- Alfresa to Tie Up with 4 Wholesalers
April 19, 2010
ページ
Japan is ramping up its push to spread regional formularies nationwide, a policy expected to standardize treatments, strengthen supply resilience,…
We had just gotten off a call with a client in Europe, and we’d received a bit of an earful. “Philip,” the client pressed, “what can this candidate bring to us? We know what he does, but what has he…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…